Calliditas Therapeutics AB announced publication in The Lancet of the full data from the Phase 3 NefIgArd Study with Nefecon® delayed release capsules/Kinpeygo®) in adults with Primary IgA nephropathy.
Asieris Pharmaceuticals announced that the Government of Hong Kong Special Administrative Region Department of Health has approved the registration applications for the Uro-G and Uro-V disposable cystoscopic system.
Scientists at City of Hope, one of the largest cancer research and treatment organizations in the United States and a leading research center for diabetes and other life-threatening illnesses, have identified a cell metabolism process found in men with diabetes and metastatic prostate cancer that could one day lead to improved testing and treatments for
Aurisco Pharmaceutical announced that its API and FDF plant in Yangzhou, China has successfully passed a cGMP inspection by the US Food and Drug Administration.
Successful FDA inspection at Aurisco’s manufacturing site in Yangzhou, China Read More »
Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced the results of the first six months and second quarter ending June 30, 2023 and provided a corporate update.
Mainz Biomed Announces Financial Half Year Results 2023 and Provides Corporate Update Read More »
Basilea Pharmaceutica Ltd, Allschwil, a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial or fungal infections, announced its financial results for the first half-year ended June 30, 2023.
Basilea reports strong revenue and profit growth in first half-year 2023 Read More »
Spexis AG announced a capital commitment totaling USD $2.5 million with participation from SPRIM Global Investments and institutional investors to fund the upcoming Phase 3 ColiFin® studies, beginning with the COPILOT study which is expected to initiate in the third quarter of 2023.
Revisión sobre el manejo y las opciones de tratamiento del acné vulgar en adolescentes.
Una revisión y puesta al día | Acné vulgar en adolescentes Read More »
For the third year in a row, demand for nurses surpassed what’s been seen in other specialties, according to a report from staffing firm AMN Healthcare.
Demand for nurse practitioners exceeded other specialty providers, report finds Read More »
The health system alleges providers have lost at least $19 billion per year as a direct result of MultiPlan’s anticompetitive agreements with major payers, including UnitedHealth, Aetna and Elevance.
AdventHealth sues MultiPlan for alleged ‘cartel’ with health insurers to fix prices Read More »
